Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis
Roland M. du Bois(Imperial College London), Talmadge E. King(University of California, San Francisco), Lisa Lancaster(Vanderbilt University Medical Center), Alex Kartashov(Policy Analysis (United States)), Carlo Albera(University of Turin), Michiel Thomeer(Universitair Ziekenhuis Leuven), Derek Weycker(Policy Analysis (United States)), Williamson Z. Bradford(InterScience (United States)), Paul W. Noble(Cedars-Sinai Medical Center), Ulrich Costabel(Ruhrlandklinik), Steven A. Sahn(Medical University of South Carolina), Javier Szwarcberg(InterScience (United States)), Dominique Valeyre(Inserm), Ganesh Raghu(University of Washington)
Cited by 429
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
|Immunity|2009|2.3k
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
|The Lancet|2011|2.1k
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2006|1.3k